Amarin Corporation plc
NASDAQ:AMRNBiotechnology
+$0.29 today
- Market cap
- $232.89M
- Beta
- 0.82
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$1.62
Volume 0.09M
Average 0.07M
AMRN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Amarin Corporation plcNASDAQ: AMRN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $4.67M fell 12.2% year over year, behind the -6.9% change in trailing-twelve-month research & development. Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at -13.3% a year.
Context
- Research & development amounted to 9.3% of revenue in FY2025, up 0.1 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -12.2% toward the trailing-twelve-month pace of -6.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 19.81M USD
- Year-over-year change
- -5.1%
- 4-year CAGR
- -9.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.81M | -5.1% |
| FY2024 | 2024-12-31 | 20.87M | -6.1% |
| FY2023 | 2023-12-31 | 22.22M | -26.9% |
| FY2022 | 2022-12-31 | 30.41M | +3.8% |
| FY2021 | 2021-12-31 | 29.31M | — |
Research & Development vs competitors
How AMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -6.9% is the 6th highest of 10, against a peer median of +5.0%.
- Research & development amounts to 8.6% of revenue for AMRN, versus a peer median of 4120.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $152.7M USD | +75.7% | +85.3% | — | |
| LTM Mar 2026 | $151.83M USD | -11.7% | -0.1% | 489780.6% | |
| LTM Mar 2026 | $124.71M USD | +42.2% | +15.6% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $98.75M USD | +56.7% | +82.8% | — |
| LTM Mar 2026 | $94.68M USD | +5.0% | -1.4% | 139.0% | |
| LTM Mar 2026 | $66.77M USD | -12.8% | -2.0% | 185483.3% | |
| LTM Mar 2026 | $61.84M USD | — | +24.0% | 6710.8% | |
| LTM Mar 2026 | $58.79M USD | -15.8% | +15.8% | 1530.1% | |
| LTM Mar 2026 | $55.94M USD | +19.0% | +24.4% | — | |
| LTM Mar 2026 | CHF 52.18M CHF | -17.6% | -2.2% | 1409.6% | |
| LTM Mar 2026 | $18.45M USD | -6.9% | -13.3% | 8.6% | |
| Peer median (excluding AMRN) | — | +5.0% | +15.7% | 4120.5% | |
Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 583.19M | 369.19M | 306.91M | 228.61M | 213.65M |
| Cost of Revenue | 121.33M | 126.71M | 141.37M | 147.23M | 92.78M |
| Gross Profit | 461.86M | 242.48M | 165.54M | 81.38M | 120.87M |
| Gross Margin | 79.2% | 65.7% | 53.9% | 35.6% | 56.6% |
| Research & Development | 29.31M | 30.41M | 22.22M | 20.87M | 19.81M |
| Selling, General & Admin | 408.33M | 304.42M | 199.94M | 152.31M | 115M |
| Operating Expenses | 451.36M | 348.35M | 222.16M | 173.18M | 134.81M |
| Depreciation & Amortization | 2.86M | 3.1M | 2.97M | 3.01M | 3.03M |
| EBITDA | 14.28M | (100.69M) | (50.7M) | (74.18M) | (33.01M) |
| EBITDA Margin | 2.4% | -27.3% | -16.5% | -32.4% | -15.5% |
| Operating Income | 10.5M | (105.87M) | (56.62M) | (91.8M) | (13.94M) |
| Operating Margin | 1.8% | -28.7% | -18.4% | -40.2% | -6.5% |
| Interest Income | 1.22M | 2.82M | 11.86M | 13.4M | 10.85M |
| Interest Expense | 129K | 15K | 8K | 7K | 7K |
| Other Income / Expenses | 789K | 2.06M | 2.95M | 14.6M | (22.11M) |
| Income Before Tax | 11.29M | (103.81M) | (53.67M) | (77.2M) | (36.05M) |
| Pre-Tax Margin | 1.9% | -28.1% | -17.5% | -33.8% | -16.9% |
| Income Tax Expense | 3.56M | 2M | 5.44M | 4.98M | 2.75M |
| Net Income | 7.73M | (105.8M) | (59.11M) | (82.18M) | (38.8M) |
| Net Margin | 1.3% | -28.7% | -19.3% | -35.9% | -18.2% |
| EPS (Basic) | 0.39 | (5.20) | (3.00) | (4.00) | (1.80) |
| EPS (Diluted) | 0.38 | (5.20) | (3.00) | (4.00) | (1.80) |
| Weighted Avg Shares | 19.8M | 20.06M | 19.7M | 20.55M | 20.75M |
| Weighted Avg Shares (Diluted) | 20.12M | 20.06M | 20.38M | 20.55M | 20.75M |
Amarin Corporation plc
NASDAQ:AMRN
Intrinsic Alpha fair value
Locked
Current Price
$11.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.